- Conditions
- Neurofibromatosis Type 1
- Interventions
- Not listed
- Lead sponsor
- Shriners Hospitals for Children
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 5,597
matching trials from the live ClinicalTrials.gov search.
- Conditions
- NF1, Neurofibromatosis, Plexiform Neurofibromas
- Interventions
- Cabozantinib
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
- Conditions
- Alzheimer's Disease
- Interventions
- Simvastatin, Placebo
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 45 Years to 64 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Parkinson's Disease, Perception, Visual Hallucination
- Interventions
- Not listed
- Lead sponsor
- Boston University Charles River Campus
- Other
- Eligibility
- 40 Years to 110 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer Disease, Amyloid Beta-Protein
- Interventions
- Florbetaben (BAY94-9172)
- Drug
- Lead sponsor
- Lantheus Biosciences Ltd.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 422 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 7
- States / cities
- Sun City, Arizona • Stanford, California • New Haven, Connecticut + 3 more
- Conditions
- Alzheimer's Disease, Dementia, Healthy, Memory Disorder
- Interventions
- Not listed
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1995 – 2007
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Pittsburgh, Pennsylvania
- Conditions
- Myasthenia Gravis
- Interventions
- Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
- Drug
- Lead sponsor
- Muscular Dystrophy Association
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Tourette Syndrome
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 14 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Tourette Syndrome
- Interventions
- d-cycloserine, Placebo pill, Behavior Therapy
- Drug · Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 8 Years to 17 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Batoclimab 680 mg SC weekly, Batoclimab 340 mg SC weekly, Matching Placebo SC, Batoclimab 340 mg SC bi-weekly
- Drug
- Lead sponsor
- Immunovant Sciences GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Carlsbad, California + 27 more
- Conditions
- Dementia, Alzheimer's Type, Alzheimer's Disease
- Interventions
- SAR448851, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 8
- States / cities
- Oakland, California • Naples, Florida • The Villages, Florida + 5 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Zilucoplan
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Denton, Texas
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- BIIB100, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 6 more
- Conditions
- Tourette Syndrome in Adolescence, Tourette Syndrome, Tourette Syndrome in Children
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Neurofibromatosis, Neurofibromatosis I, Neurofibromatosis 2, Schwannomatosis
- Interventions
- The Relaxation Response Resiliency Program (3RP) via Skype
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer Disease, Psychomotor Agitation
- Interventions
- prazosin, placebo (inert substance)
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- Not listed
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Tourette Syndrome, Persistent Tic Disorder
- Interventions
- CBIT
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- San Diego, California • Minneapolis, Minnesota
- Conditions
- Central Visual Impairment, Macular Degeneration
- Interventions
- Training visual sensitivity, Combination training
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Parkinson's Disease
- Interventions
- XP21279 and carbidopa (experimental), Sinemet (comparator), Placebo for XP21279 and carbidopa, Placebo for Sinemet
- Drug
- Lead sponsor
- XenoPort, Inc.
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 9 more
- Conditions
- Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
- Interventions
- Cerliponase Alfa, Administration Kit
- Drug · Device
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- Not listed
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 16
- States / cities
- Little Rock, Arkansas • Orange, California • Aurora, Colorado + 12 more
- Conditions
- Alzheimer's Disease
- Interventions
- Crenezumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 813 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 66
- States / cities
- Phoenix, Arizona • Encino, California • Long Beach, California + 56 more
- Conditions
- Tourette Syndrome, Obsessive Compulsive Disorder
- Interventions
- Not listed
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1989
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Parkinson's Disease
- Interventions
- ND0612
- Drug
- Lead sponsor
- NeuroDerm Ltd.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 23 more
- Conditions
- Dementia With Lewy Bodies
- Interventions
- Neflamapimod, Placebo
- Drug
- Lead sponsor
- EIP Pharma Inc
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 26 more